Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Trueman, D. [1 ]
Ndirangu, K. [2 ]
Paine, A. [1 ]
Pilkington, H. [1 ]
机构：
[1] Source Hlth Econ, Hlth Econ & Stat, London, England
[2] Eisai Inc, Global Value & Access, Nutley, NJ USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1007P
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 50 条
  • [21] An Indirect Treatment Comparison of Lenvatinib for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Ndirangu, Kerigo
    Paine, Abby
    Pilkington, Hollie
    Trueman, David
    ADVANCES IN THERAPY, 2025, 42 (02) : 977 - 994
  • [22] Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    ONCOLOGIST, 2020, 25 (03): : E512 - E519
  • [23] Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC)
    Alsina, Angel
    Kudo, Masatoshi
    Vogel, Arndt
    Cheng, Ann-Lii
    Tak, Won Young
    Ryoo, Baek-Yeol
    Evans, T. R. Jeffry
    Lopez, Carlos Lopez
    Daniele, Bruno
    Blanc, Jean-Frederic
    Ren, Min
    Baldwin, Rae Lynn
    Izumi, Namiki
    Qin, Shukui
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
    Ciliberto, Domenico
    Carid, Giulio
    Staropoli, Nicoletta
    Romeo, Caterina
    Arillotta, Grazia Maria
    Napoli, Cristina
    Gervasi, Luigia
    Luciano, Francesco
    Riillo, Caterina
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    HELIYON, 2023, 9 (08)
  • [25] First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials
    Liu, Wenfeng
    Quan, Bing
    Lu, Shenxin
    Tang, Bei
    Li, Miao
    Chen, Rongxin
    Ren, Zhenggang
    Yin, Xin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
    Galle, Peter Robert
    Decaens, Thomas
    Kudo, Masatoshi
    Qin, Shukui
    Fonseca, Leonardo
    Sangro, Bruno
    Karachiwala, Hatim
    Park, Joong-Won
    Gane, Edward
    Pinter, Matthias
    Tai, David
    Santoro, Armando
    Pizarro, Gonzalo
    Chiu, Chang-Fang
    Schenker, Michael
    He, Aiwu Ruth
    Wang, Qi
    Stromko, Caitlyn
    Hreiki, Joseph
    Yau, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4008 - LBA4008
  • [27] Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta-analysis
    Li, Yong
    Liu, Xingyu
    Liu, Junning
    Yang, Linfeng
    Wei, Song
    Li, Jijiang
    Gan, Huixin
    Ma, Ting
    Yi, Pengsheng
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [28] Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
    Casadei-Gardini, Andrea
    Scartozzi, Mario
    Tada, Toshifumi
    Yoo, Changhoon
    Shimose, Shigeo
    Masi, Gianluca
    Lonardi, Sara
    Frassineti, Luca Giovanni
    Nicola, Silvestris
    Piscaglia, Fabio
    Kumada, Takashi
    Kim, Hyung-Don
    Koga, Hironori
    Vivaldi, Caterina
    Solda, Caterina
    Hiraoka, Atsushi
    Bang, Yeonghak
    Atsukawa, Masanori
    Torimura, Takuji
    Tsuj, Kunihiko
    Itobayashi, Ei
    Toyoda, Hidenori
    Fukunishi, Shinya
    Rimassa, Lorenza
    Rimini, Margherita
    Cascinu, Stefano
    Cucchetti, Alessandro
    LIVER INTERNATIONAL, 2021, 41 (06) : 1389 - 1397
  • [29] Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Meng, Rui
    Zhang, Xueke
    Zhou, Ting
    Luo, Mengjie
    Qiu, Yijin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1079 - 1086
  • [30] ASSESSING THE COST-EFFECTIVENESS OF LENVATINIB AS A FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CANADA
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E3 - E4
12345